Kuros Biosciences AG

Kuros Biosciences AG

CSBTF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$950.56M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Kuros Biosciences AGKuros Biosciences AG107.6-1%40.2

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$950.56 Million
Enterprise Value$953.72 Million
Earnings per Share$0.06
Beta0.76
Outstanding Shares39,458,790

Return

Return on Equity1.42%ROE
Return on Assets0.85%
Return on Invested Capital9.72%

Valuation & Multiples

P/E Ratio107.57P/E Ratio
PEG-39.52PEG
Price to Sales4.02Price to Sales
Price to Book Ratio24.09Price to Book Ratio
Enterprise Value to Revenue3.88
Enterprise Value to EBIT116.41
Enterprise Value to Net Income931
Total Debt to Enterprise0.01
Debt to Equity0.15Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
August 13, 2026
EPS
$0.11
Reported
Revenue
$92.40 M
Est. $91.00 M

Next Earnings Call

Expected Date
March 3, 2027
EPS Estimate
-
Consensus analyst estimate
Revenue Estimate
$111.60 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Kuros Biosciences AG

178 employees
CEO: Christopher T. Fair

Kuros Biosciences AG operates as a biopharmaceutical firm, concentrating on the commercialization and advancement of products designed for tissue repair and bone regeneration. Its operations span the United States, the European Union, an...